The Epidemiological, Therapeutic and Evolutionary Profile of Breast Medullary Carcinoma

J Achrane H, Asmouki and M Khouchani
Additional contact information
J Achrane H: Gynecology service, Mother and Child Hospital. Mohamed VI Teaching Hospital, Morocco
M Khouchani: Oncology department, Mother and Child Hospital. Mohamed VI Teaching Hospital, Morocco

Cancer Therapy & Oncology International Journal, 2020, vol. 15, issue 3, 91-95

Abstract: Breast Medullary carcinoma is a histologic form with inflammatory stroma requiring strict histological criteria for its definition (RIDOLFI 1977). It represents less than 5% of breast tumors. The aim of this work is to analyse the epidemiological, clinical, evolutive characteristics and therapeutic results, through a retrospective study of medullary breast carcinoma histologically confirmed and treated in the oncology department of the university hospital of Marrakech city during a period of five years, from 2007 to 2012. 17 cases of medullary carcinoma were collected as 2.2 % of breast cancers treated during the same period. The average age was 47 years (30-58 years). The average tumor size was 4 cm with axillary lymph nodes in 6 cases (35%). The common site was the upper outer quadrant in 47 % of cases. 30% of cases showed a typical medullary carcinoma. And estrogenic or progesterone hormone receptors were negative in 9 cases (52%) and HER negative in 5 patients (47%). All typical carcinomas were “triple negative†. Conservative surgery was performed in 47% of cases, while a total mastectomy with lumpectomy involved 53% of the remaining patients. Chemotherapy was administered in 88% of patients. Postoperative radiotherapy was performed in 94% of cases. 35 % of patients had received adjuvant hormonal therapy, two patients had received targeted therapy. With a median follow of 25 months, only one case of recurrence was reported, no cases of metastasis or death was noted. This study confirms the favourable evolution of the medullary breast cancer despite poor prognostic factors often found in these rare tumors

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555912.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555912.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:15:y:2020:i:3:p:91-95

DOI: 10.19080/CTOIJ.2020.15.555912

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().